NVCT as of Oct 31 · 00:00 ET

NVCTNasdaqPharmaceutical Preparations

Nuvectis Pharma, Inc. · Brief

Next report

3 days

Nov 3 · before openest.Q3 FY26

Earnings

Expected move

Inputs

±14.7%implied · straddle

15.7621.20

spot 18.48exp Nov 20ATM strike 17.5ATM straddle 3.20IV 87%

Oct 30 close

Expected move

Inputs

Implied vs realized

8 reportsHistory

0 of 7≥ implied

avg implied: ±44.6%
avg realized: ±5.7%

Nov 5 '24—▲+17.75%—

Feb 25 '25±18.8%▼−5.84%×0.31

May 6 '25±18.7%▼−4.38%×0.23

Aug 5 '25±43.0%▼−5.35%×0.12

Nov 4 '25±52.7%▼−7.55%×0.14

Feb 11 '26±83.7%▲+0.46%×0.01

Q1 FY26±56.7%▲+9.22%×0.16

Q2 FY26±38.9%▼−6.94%×0.18

quarterimplied−85%0+85%realized×

Q2 FY26±38.9%▼−6.94%×0.18

Q1 FY26±56.7%▲+9.22%×0.16

Feb '26±83.7%▲+0.46%×0.01

Nov '25±52.7%▼−7.55%×0.14

Aug '25±43.0%▼−5.35%×0.12

May '25±18.7%▼−4.38%×0.23

2 older reports

Feb '25±18.8%▼−5.84%×0.31

Nov '24—▲+17.75%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 3 report · est.

Bull2 of 3

4disclosed supplier and customer ties in SEC filings with counterpartiesSEC filings

1 of 17of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

Bear2 of 3

7 of 7recent reports where the move came in under the options-implied rangeEarnings history

3tracked funds holding NVCTN-PORT · Aug 31 '26

AI captions · Sep 16 '26once per report · top 2 per case

Linked exposure

NVCT report session

No linked exposure.

Latest changes

30 daysAll changes

Oct 20impliedImplied move: ±20.4% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.